The situation of the NASDAQ

 The situation of the NASDAQ

Τhe situation of the Greek stock market

 The situation of the Greek stock market

Α΄KOSTOLANY EGG (NASDAQ) 12-22-2021

 

Α΄KOSTOLANY EGG  (NASDAQ)

A' KOSTOLANY EGG ATHEX - GREECE 12-22-2021

 A' KOSTOSTOLANY EGG ATHEX - GREECE 12-22-2021

Alibaba Group (NYSE:BABA) Stock Rating Lowered by Atlantic Securities

 Alibaba Group (NYSE:BABA) Stock Rating Lowered by Atlantic Securities

BioDelivery Sciences posts a record gain after favorable court ruling

 BioDelivery Sciences posts a record gain after favorable court ruling

Corsair Gaming, Inc. (CRSR-NASDAQ) CASH $

 Corsair Gaming, Inc. (CRSR-NASDAQ) CASH $ 

BAYER:U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children

 

U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prevent VTE in children

Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing / Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age / Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives   ... ... ... ... Blood clots ... ... ... ...

Berlin, December 21, 2021 – The U.S. Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto™ (rivaroxaban): the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of VTE and VTE related events) in children aged two years and older with congenital heart disease who have undergone the Fontan procedure.

Corsair Gaming, Inc. NET INCOME 2015-2020

 Corsair Gaming, Inc. (CRSR-NASDAQ) NET INCOME $ 

Corsair Gaming, Inc. (CRSR-NASDAQ) REVENUE $

 Corsair Gaming, Inc. (CRSR-NASDAQ) REVENUE $